Get instant access to this case solution for only $9
Napo Pharmaceuticals Case Solution
| Solution Id | Length | Case Author | Case Publisher |
|---|---|---|---|
| 1780 | 309 Words (2 Pages) | Robert Chess, Joshua Spitzer | Stanford Graduate School of Business : E223 |
A Word File
The case discusses the negotiation deal that is taking place between Napo Pharmaceuticals, Public Health International (PHI), and Robert and Diane Gelb Foundation (Gelb). The deal would help in the development of a drug that could help save the lives of millions of children affected with diarrhoea.
Following questions are answered in this case study solution
-
Background
-
Recommendation
-
Next Steps
Case Analysis for Napo Pharmaceuticals
Moreover, the deal would provide Napo with $6 million in payments, which if not received, could make Napo go bankrupt by February 2005. The problem in the case is that, even after 2 years of negotiations, the deal has not been finalized. The people from Napo are not willing to give away their IP rights to the drug Crofelemer that they developed. This is because Napo aims to develop partnerships with other companies and also that this IP was its principal asset. PHI, on the other hand, was concerned that if Napo goes bankrupt, they would lose the supply of Crofelemer. Therefore, they insisted on acquiring certain IP rights for the drug. The root cause is that either side is not considering the problem from the other’s perspective.
Get instant access to this case solution for only $9
Get Instant Access to This Case Solution for Only $9
Standard Price
$25
Save $16 on your purchase
-$16
Amount to Pay
$9
Different Requirements? Order a Custom Solution
Calculate the Price
Related Case Solutions
Get More Out of This
Our essay writing services are the best in the world. If you are in search of a professional essay writer, place your order on our website.
